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Abstract: Fatigue is a cardinal symptom in fibromyalgia. Fatigue is assumed to be the result of genetic
susceptibility and environmental factors. We aimed at examining the role of genetic susceptibility for
fatigue in southern Spanish women with fibromyalgia, by looking at single nucleotide polymorphisms
in 34 fibromyalgia candidate-genes, at the interactions between genes, and at the gene-physical
activity interactions. We extracted DNA from saliva of 276 fibromyalgia women to analyze gene-
polymorphisms. Accelerometers registered physical activity and sedentary behavior. Fatigue was
assessed with the Multidimensional Fatigue Inventory. Based on the Bonferroni’s and False Discovery
Rate values, we found that the genotype of the rs4453709 polymorphism (sodium channel protein type
9 subunit alpha, SCN9A, gene) was related to reduced motivation (AT carriers showed the highest
reduced motivation) and reduced activity (AA carriers showed the lowest reduced activity). Carriers
of the heterozygous genotype of the rs1801133 (methylene tetrahydrofolate reductase, MTHFR,
gene) or rs4597545 (SCN9A gene) polymorphisms who were physically active reported lower scores
on fatigue compared to their inactive counterparts. Highly sedentary carriers of the homozygous
genotype of the rs7607967 polymorphism (AA/GG genotype; SCN9A gene) presented more reduced
activity (a dimension of fatigue) than those with lower levels of sedentary behavior. Collectively,
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findings from the present study suggest that the contribution of genetics and gene-physical activity
interaction to fatigue in fibromyalgia is modest.
Keywords: accelerometry; chronic pain; epidemiology; gene polymorphism; rehabilitation; treatment
1. Introduction
Fibromyalgia is a disease characterized by chronic widespread pain and increased
sensitivity to painful stimuli [1]. Although the pathophysiology of fibromyalgia re-
mains unknown, family aggregation suggests a role of genetics in fibromyalgia [2]. Tra-
ditionally, most of the candidate-genes studied in fibromyalgia are related to neuro-
transmitters [3,4]. For instance, the most extensively studied gene is the catechol-O-
methyltransferase (COMT), which participates in degrading catecholamines and several
other neurotransmitters and, therefore, in modulating pain perception by the central ner-
vous system. Findings of the previous literature regarding COMT gene and susceptibility
to fibromyalgia are inconclusive [5,6], therefore, research has aimed at identifying new
candidate genes; see [3,7]. For instance, the sodium voltage-gated channel alpha subunit 9
(SCN9A) gene have been recently proposed as part of the pathogenesis of fibromyalgia [8].
Mutations of the SCN9A gene may be related to upregulation of the sodium channels and,
consequently, to hyperreactivity to nociceptive stimulus [9].
Currently, the diagnosis of fibromyalgia is undergoing some changes, and fatigue is
now included as part of the clinical diagnostic criteria [10]. Indeed, fatigue is markedly
high in fibromyalgia, e.g., it is severe in 82% of people with the disease [11]. People
living with the disease identify fatigue as one of the main symptoms, with 25% of them
identifying fatigue as the main symptom of the disease [12]. In fibromyalgia, fatigue is a
distressing symptom that is associated with reduced health-related quality of life [13,14].
Most of the previous studies analyzed the association between candidate genes and a
total score of symptoms of fibromyalgia (e.g., [15,16]); mostly using the total score of the
Fibromyalgia Impact Questionnaire (FIQ). Unfortunately, this approach does not allow to
study the determinants of specific key symptoms such as the levels of fatigue experienced
by people with fibromyalgia. Collectively, previous findings suggest that the contribution
of genetics to fibromyalgia is modest, which is expected because fibromyalgia is considered
a very complex disease phenotype [7]. Therefore, it is hypothesized that the experience of
fatigue in fibromyalgia is better understood as a genetic susceptibility that is modulated by
environmental factors [4,17].
Epigenetic mechanisms represent a link between gene and environment [18] as it has
been demonstrated in fibromyalgia [19] and similar diseases characterized by disabling
fatigue (e.g., chronic fatigue syndrome) [20]. For instance, in people with chronic fatigue
syndrome, increments in hypomethylation in promoter and regulatory regions of immune
genes compared to other gene classes have been previously observed [20]. It has also
been suggested that DNA methylation patterns in serum brain-derived neurotrophic fac-
tor (sBDNF) are key mechanisms explaining the pathophysiology of fibromyalgia and
persistent fatigue [21]. Associations between fibromyalgia and single nucleotide polymor-
phism affecting the serotonergic, dopaminergic and catecholaminergic pathways have been
identified via candidate gene analyses. Of them, those genes related to the serotonergic
pathway and affecting ion channels are relevant in the levels of fatigue experienced by
people with fibromyalgia [22]. Alteration of protein expression, potentially regulated by
microRNA, may also play a role in fibromyalgia [23]. Indeed, it has been observed that
alterations in microRNA are related to fatigue in people with fibromyalgia [24,25]. For
instance, in comparisons to controls, the expression levels of miR-145-5p are reduced in
fibromyalgia [25]. Additionally, lower levels of miR-145-5p expression are associated with
more fatigue in fibromyalgia [25]. Therefore, gene-environment interactions may help to
better understand the levels of fatigue in people with fibromyalgia.
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When considering complex symptoms such as fatigue in fibromyalgia, gene-environmental
interactions are likely present and can help to better understand the disease (e.g., unravel
underlying mechanisms [26]). Among environmental exposures, physical activity (any bod-
ily movement produced by skeletal muscles that results in energy expenditure above basal
metabolic rate [27]) and sedentary behavior (activity performed while awake that is done in
a seated or lying position and does not increase energy expenditure substantially [27]) are
major determinants of health and disease [28]. Research has convincingly demonstrated
that higher physical activity and lower sedentary behavior is beneficial for lowering fatigue
in the general population [29] and diseases (e.g., cancer [30] and fibromyalgia [31,32]).
Indeed, physical activity is a first-line non-pharmacological treatment for fibromyalgia
symptoms [33] (including fatigue [31]). Despite the importance of physical activity and
sedentary behavior in fibromyalgia, previous research did not consider the interplay of
genes and these behaviors. From a clinical and public health perspective, to understand the
interplay between genetics and physical activity on fatigue in fibromyalgia is of interest.
Therefore, this study aimed to comprehensively examine the singular association
between genotype and fatigue, the interaction between genes, and the association between
genes and physical activity/sedentary behavior with fatigue, which may lead to a better
understanding of the biological and behavioral mechanisms of fatigue in people with
fibromyalgia.
2. Materials and Methods
2.1. Study Design and Population
The design of the present study was cross-sectional. As described elsewhere [34],
we calculated the sample size needed to obtain a representative sample of women with
fibromyalgia from the Andalusian (Southern Spain) population, i.e., n = 240. Next, we
followed a province-proportional recruitment strategy [34]. The participants (i) were re-
cruited mainly via fibromyalgia associations from Andalusia (Southern Spain), (ii) had been
previously diagnosed with fibromyalgia by a rheumatologist and met the 1990 American
College of Rheumatology (ACR) criteria for fibromyalgia, which was further confirmed
by a tender point examination [1], and (iii) signed an informed consent form. The Ethics
Committee of the Virgen de las Nieves Hospital (Granada, Spain) approved the study (Reg-
istration number: 15/11/2013-N72). We followed the ethical guidelines of the Declaration
of Helsinki.
2.2. Measures Related to Potential Confounders or Inclusion/Exclusion Criteria
Socio-demographic and clinical data. The participants filled out an initial question-
naire that included questions about date of birth, marital status, working status, and
educational level, and presence/absence of acute or terminal illness (such as cancer, stroke,
recent cardiomyopathy, severe coronary disease, schizophrenia, or any other disabling
injury). The consumption of analgesics and antidepressants was registered as binary
variables (yes/no).
Body fat (%) was measured using a portable eight-polar tactile-electrode impedan-
ciometer (InBody R20, Biospace, Seoul, Korea). During the assessment, the participants
were barefoot and they wore only underwear and no metal objects.
2.3. Measures Related to Genetic Analysis
As described elsewhere [4,35], samples were genotyped for 64 polymorphisms that had
been previously investigated in relation to fibromyalgia susceptibility, symptoms, or potential
mechanisms. We collected samples of buccal mucosa cells and performed DNA non-organic
extraction (proteinase K and salting-out) procedures prior the spectrophotometric quantification
(NanoDrop 2000c, ThermoFisher, Waltham, MA, USA). The data were analyzed using the
TaqMan®Genotyper Software (ThermoFisher, Waltham, MA, USA) and downstream analysis
using the AutoCaller™ Software.2.4 (ThermoFisher, Waltham, MA, USA).
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2.4. Measures of Physical Activity and Sedentary Time
Triaxial accelerometers GT3X+ (Actigraph, Pensacola, FL, USA) were used to objec-
tively measure physical activity and sedentary behavior during a time interval of seven
continuous days with a minimum of 10 valid hours per day. Binary data of physical
activity and sedentary behavior were recorded as follows (i) fulfilment (yes/no) of the
physical activity recommendations (≥150 min/week of moderate to vigorous physical
activity in bouts of, at least, 10 min of duration and, (ii) sedentary behavior (low/high)
using the mean (459.1 min/day) as the cut-off value. Among the available brands, the
Actigraph accelerometers (Actigraph, Pensacola, FL, USA) are clearly the most widely
used in research [36,37]. Against doubly labelled water (the gold standard for measuring
physical activity and sedentary behavior), the Actigraph (Actigraph, Pensacola, FL, USA)
accelerometers are valid [38].
2.5. Measures Related to Fatigue
The Spanish version of the Multidimensional Fatigue Inventory (MFI) [39] was used
to assess five dimensions of fatigue; namely, general fatigue (e.g., I feel tired), physical
fatigue (e.g., physically I feel only able to do a little), mental fatigue (e.g., it takes a lot
of effortto concentrate on things), reduced activity (e.g., I get little done), and reduced
motivation (e.g., I don’t feel like doing anything). It should be noted that fatigue is by
nature multidimensional, including physical and psychological domains [40,41]. The MFI
accounts for this multidimensionality. The score ranges of the five dimensions is 4 to 20.
The psychometric properties of the Spanish version of the MFI are adequate in people with
fibromyalgia [39].
2.6. Statistical Analysis
All analyses were performed in the R environment v.3.4.1. The Hardy-Weinberg
equilibrium (HWE; p > 0.01) and linkage disequilibrium (r2 > 0.5) were evaluated with
‘genetics’ package [42]. Gene-phenotype associations along with gene-gene interactions
were assessed with the ‘SNPassoc’ package [43]. We developed our own script to study
gene-environment interactions.
To analyze the singular associations of polymorphisms with phenotypes, we computed
general linear models with age, body fat (%), and the consumption of analgesics and
antidepressants as covariates. Interactions between polymorphisms of different genes as
well as between polymorphisms and physical activity or sedentary behavior were assessed
using the same models but including their interaction terms in separate models. We
considered as significant those associations with either p-values lower than the Bonferroni’s
correction or with both p-values and false discovery rate (FDR) values lower than 0.05.
3. Results
A total of 276 women participated in the present study. The participants have a
mean age of 51.8 years (SD = 7.7), mostly are married (77.9%), and about half of them
have finished primary school (50.9%). Furthermore, 36.2% of the participants were either
on incapacity benefit, sick leave, or unemployed. The average sedentary behavior was
459.1 min/day (SD = 107.9), see Table 1.
The rs6323, rs7911, rs806377, rs1050450, rs1137070, rs3746544, rs4411417, and rs7124442
polymorphisms did not meet the HWE criteria. A low genotyping rate (i.e., ≤0.90) was
observed for the rs4371369, rs4387806, rs6746030, rs7310505, rs9470080, and rs12620053
polymorphisms. The remaining 50 polymorphisms were included in the present study.
Figure 1 shows that the AT genotype of the rs4453709 (SCN9A gene) showed that
higher levels of reduced motivation than the AA/TT genotype (overdominant model,
p = 0.0004 and FDR = 0.016) and that the genotype AA of the same polymorphism showed
lower levels of reduced activity than the AT/TT genotype (dominant model, p = 0.0008
and FDR = 0.031). The remaining individual associations between genotype and fatigue
outcomes were not significant (data not shown but available under reasonable request).
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Table 1. Characteristics of the participants in the study, n = 276.
Clinical and Sociodemographic Information n (%)
Education Level
Unfinished studies 26 (9.4)
Primary 139 (50.4)
















Clinical and sociodemographic information Mean (SD)
Age, years old 51.8 (7.7)
Body fat (%) 40.4 (7.6)
Tender points count (0–18) 16.9 (1.8)
Physical activity and sedentary behaviour
Moderate-to-vigorous physical activity
(min/week) 87.0 (119.2)
Sedentary behaviour (min/day) 459.1 (107.9)
Fatigue (MFI, 4–20)
General fatigue 18.0 (2.5)
Physical fatigue 16.4 (3.1)
Reduced activity 12.8 (4.9)
Reduced motivation 12.9 (4.0)
Mental fatigue 14.7 (2.4)
SD, standard Deviation; MFI, multidimensional fatigue inventory.
All the gene-gene interactions were not statically significant (data not shown but
available under reasonable request).
A number of significant gene-physical activity interactions emerged. Figure 2 shows
the significant interactions involving methylene tetrahydrofolate reductase (MTHFR) gene.
Particularly, amongthe among carriers of the CT genotype of the rs1801133 (methylene
tetrahydrofolate reductase, MTHFR, gene), those who met the physical activity recom-
mendations showed lower physical fatigue and reduced motivation than those who did
not meet such physical activity levels; p = 0.0002, FDR = 0.01 and p = 0.0025 and FDR
= 0.042, respectively. Figure 3 shows the significant interactions involving the SCN9A
gene. Particularly, in the participants carrying the CG genotype of the rs4597545 (SCN9A
gene), in comparison to those who engage in low levels, the participants that had increased
levels of physical activity reported lower mental fatigue, which was corroborated across
different models: p = 0.0003 and FDR = 0.012 for codominant, p = 0.0058 and FDR = 0.047 for
recessive, and p = 0.0001 and FDR = 0.004 for overdominant. A set of statistically significant
additive associations were not interpreted as such given that they lacked statistical power
(i.e., n ≤ 10 in some genotypes): of the rs1801133 (MTHFR gene) and physical activity
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with mental fatigue, and of the rs6860 (CHMP1A gene) and physical activity with mental
fatigue, both under the recessive model. The remaining additive associations of genotype
and physical activity with fatigue outcomes did not reach the significance (data not shown
but available under reasonable request).
Figure 1. Individual associations of the genotype of the rs4453709 polymorphism (SCN9A gene) with dimensions of fatigue;
i.e., reduced motivation (left panel) and reduced activity (right panel). Note. SCN9A, sodium voltage-gated channel alpha
subunit 9 gene; MFI, multidimensional fatigue inventory (MFI, scores range 0–20). According to the p- and false discovery
rate (FDR) values, all these associations of genotype and fatigue were significant.
Figure 2. Associations of the interaction of the MTHFR gene (rs1801133 polymorphism)-physical activity with dimensions
of fatigue; physical fatigue (left panel) and reduced motivation (right panel). Note. MTHFR, methylene tetrahydrofosfate
reductase gene; MVPA, moderate to vigorous physical activity; MFI, multidimensional fatigue inventory (scores range
0–20). Physical activity was objectively measured using triaxial accelerometers GT3X+ (Actigraph, Pensacola, FL, USA). We
dichotomized data of physical activity according to the fulfilment (yes vs. no) of the physical activity recommendations
(≥150 min/week) of MVPA in bouts of, at least, 10 min of length. According to the p- and false discovery rate (FDR) values,
all these gene-physical activity interactions were significant.
Only a significant gene-sedentary behavior interaction emerged. Figure 4 shows that,
in those participants carrying the AA/GG genotype of the rs7607967 (SCN9A gene), low
sedentary behavior was associated with lower scores on the reduced activity dimension of
the MFI (p = 0.0012, FDR = 0.048 for the overdominant model).
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Figure 3. Associations of the interaction of the SCN9A gene (rs4597545 polymorphism)-physical activity with mental fatigue (a
dimension of fatigue). Note. SCN9A, sodium voltage-gated channel alpha subunit 9 gene; MVPA, moderate to vigorous physical
activity; MFI, multidimensional fatigue inventory (scores range 0–20). Physical activity was objectively measured using triaxial
accelerometers GT3X+ (Actigraph, Pensacola, FL, USA). We dichotomized data of physical activity according to the fulfilment (yes
vs. no) of the physical activity recommendations (≥150 min/week of MVPA in bouts of, at least, 10 min of length. According to
the p- and false discovery rate (FDR) values, all these gene-physical activity interactions were significant.
Figure 4. Associations of the interaction of the SCN9A gene (rs7607967 polymorphisms)-sedentary
behavior with reduced activity (a dimension of fatigue). Note. SCN9A, sodium voltage-gated channel
alpha subunit 9 gene; MFI, multidimensional fatigue inventory (scores range 0–20). Sedentary
behavior as objectively measured using triaxial accelerometers GT3X+ (Actigraph, Pensacola, FL,
USA). We dichotomized data of sedentary behavior (low vs. high) using the mean as the cut-off value.
According to the p and false discovery rate (FDR) values, this gene-sedentary behavior interaction
was significant.
4. Discussion
The present study conducted in southern Spanish women with fibromyalgia showed
that the genotype of the rs4453709 (SCN9A gene) was individually related to reduced
motivation. Gene-gene interactions were not related to the phenotype of fatigue. We
observed additive associations of the genotype (i) of the rs1801133 (MTHFR gene) and
physical activity levels with physical fatigue and reduced motivation, (ii) of the rs4597545
(SCN9A gene) and physical activity levels with mental fatigue, and (iii) of the rs7607967
(SCN9A gene) and sedentary behavior with the reduced activity dimension of the fatigue
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phenotype. Therefore, the potential benefits of following an active lifestyle might be
observed more clearly in women with fibromyalgia genetically predisposed to higher
levels of fatigue.
It is widely accepted that a chronically sensitive central nervous system is part of the
pathology of fibromyalgia [5,44]. It has been hypothesized that the dorsal root ganglion
may also be hypersensitive to pain stimuli [9]. In the present study, we found that among
the rs4453709 genotype (SCN9A gene), AT carriers reported the highest reduced motivation
and AA carriers reported the lowest reduced activity. The SCN9A gene encodes a specific
type of sodium channels (i.e., the Na(v)1.7) that are located highly in the dorsal horn of
the spinal cord and in the dorsal root ganglion, the first structure is part of central nervous
system while the latter receives afferent information from the peripheral nervous system.
Thus, our findings may indicate a genetic vulnerability for reduced motivation and reduced
activity (two dimensions of fatigue) in women with fibromyalgia involving a specific part
of the central nervous system, which does not preclude a role of the peripheral one [45].
The Na(v)1.7 channels are crucial for pain signaling [46]. It is noteworthy that chronic
pain and fatigue often co-exist in fibromyalgia [47] and their mechanistic pathways may be
partly shared [48]. Moreover, the Na(v)1.7 channels are not exclusively related to pain, but
also to other sensory stimuli such as acid sensing [49] and the cough reflex [50]. Therefore,
our findings seem to extend the implication of the Na(v)1.7 channels from pain to fatigue
in women with fibromyalgia. Sodium channels are key in the generation and conduction
of action potentials. Thus, the SCN9A gene by modulating the Na(v)1.7 channels function
might be especially involved in the experiencing of symptoms by people with fibromyalgia,
particularly, reduced motivation and reduced activity. However, this speculation needs to
be corroborated in future research.
The MTHFR gene encodes an enzyme that is central in the folate metabolism as a
participant on the methionine-homocysteine cycle, which leads to DNA methylation [51].
The folate metabolism is key for feeding other biochemical cycles; its final product is an
essential precursor for several neurotransmitters (e.g., serotonin) [52], some of them are
related to fatigue (e.g., dopamine [53]). Previous literature suggested that the genotype
of the rs1801133 (MTHFR gene) is associated with fatigue in people with migraine [54],
and with stiffness and dryness in fibromyalgia [55]. Interestingly, in the present study the
association of the rs1801133 (MTHFR gene) genotype and fatigue differed according to the
physical activity levels of our participants. Additionally, metabolite abnormalities in the
hippocampus of women with fibromyalgia are also related to the clinical picture of this
disease [56]. It must be noted that the hippocampus is a core center in the appraisal of stress.
In line with our findings, physical exercise improves the levels of metabolites [57] as well
as the angiogenesis, neurogenesis, and connectivity of the hippocampus [58]. Therefore,
physical activity might be particularly beneficial for women with fibromyalgia carrying
specific genotypes. Further experimental research addressing this speculation is warranted.
Based on our findings, recommendations for future research may be considered. First,
the most robust significant associations that emerged from the present study were for the
(SCN9A and MTHFR) gene-physical activity interaction with the psychological domains
of fatigue (i.e., reduced motivation and mental fatigue). Future studies testing whether
these associations are replicated in an independent sample is warranted. Second, if they
are replicated, attention should be paid to the magnitude of the association. In the present
study, significant associations were modest and mostly for the psychological domains
of fatigue. Third, further research analyzing other important symptoms (particularly,
psychological or cognitive symptoms such as depression or difficulties performing cog-
nitive tasks involving memory) of fibromyalgia is of interest to elucidate the relevance
of the present findings in a wider context. Although the clinical relevance of the present
findings is difficult to consider, it is worth considering that fatigue in fibromyalgia is a
complex phenotype and, thus, fatigue is expected to be better explained by a combination
of many small contributions, instead of large contributions of a few factors [59]. Finally,
the European Alliance of Associations for Rheumatology (EULAR) indicated that physical
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exercise is the only therapy that has a strong level of evidence in fibromyalgia [33]. A
meta-analysis of randomized controlled trials has determined that physical exercise has
a moderate effect on reducing fatigue in fibromyalgia [31]. However, fibromyalgia is a
heterogeneous population [60,61] and, currently, no treatment alternative has shown to be
efficient, universally and in long-term in this population [31,33]. Additionally, there is large
degree of variability in individual’s response to physical exercise even when they perform
the same exercise protocol [62]. Therefore, it is of interest to determine, in future research,
whether the genotype of people with fibromyalgia predicts the effectiveness of physical
activity programs aimed at reducing the symptoms of the disease and, particularly, fatigue.
This information may be of clinical relevance in the context of personalized medicine [63].
The findings of the present study should be considered in light of its limitations.
Although unlikely given our large sample size and the inclusion of objective measurements
of physical activity and sedentary behavior for 9 consecutive days, we welcome a replication
study with an independent sample to test the robustness of the present findings. For
some polymorphisms, our sample size was not large enough for testing the gene-people’s
behavior’s interaction. On the other hand, we included a large number of candidate-genes,
physical activity and sedentary behaviors were objectively measured for 7 consecutive
days, and our results were adjusted for multiple comparisons. Although the most common
approach in the past literature was to evaluate fatigue using unidimensional scales, the
experience of fatigue is by nature multidimensional including physical and psychological
domains (e.g., physically I feel only able to do a little and I don’t feel like doing anything,
respectively) [40,41]. The inclusion of a multidimensional assessment of fatigue is also a
strength of the present study.
5. Conclusions
In conclusion, we observed an association of the genotype of the rs4453709 poly-
morphism (SCN9A gene) with reduced motivation and reduced activity. We also found
additive associations of the genotype (i) of the rs1801133 polymorphism (MTHFR gene) and
physical activity levels with physical fatigue and reduced motivation, (ii) of the rs4597545
polymorphism (SCN9A gene) and physical activity levels with mental fatigue, and (iii)
of the rs7607967 polymorphism (SCN9A gene) and sedentary behavior with the reduced
activity dimension of the fatigue phenotype. Collectively, findings from the present study
suggest that the contribution of genetics and gene-physical activity interaction to fatigue in
fibromyalgia is modest.
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